Polly Murphy, DVM, PhD

Polly has over two decades of business development and commercial strategy experience at leading global pharmaceutical companies, including 12 years in leadership positions with increasing responsibility at Pfizer. She is currently chief business officer of Avadel Pharmaceuticals and is a member of Atea Pharmaceuticals’ board of directors. Prior to Avadel she was chief business officer at UroGen Pharma from September 2020 to May 2024. While at Pfizer, she led business development for worldwide R&D and the global Specialty Care business unit, and later global marketing and commercial development for the Pfizer Oncology business unit. Polly was also vice president and head, strategy and business development for Pfizer China. Prior to Pfizer, Polly held senior leadership positions at several pharmaceutical and academic research entities, including the Scripps Research Institute, Salk Institute, and Aurora Biosciences. Polly received her DVM and PhD in veterinary pathology from Iowa State University and an MBA from Nova Southeastern University.